SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) CEO Laura Francis sold 5,248 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.29, for a total transaction of $90,737.92. Following the completion of the sale, the chief executive officer now directly owns 326,147 shares of the company’s stock, valued at approximately $5,639,081.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
SI-BONE Stock Performance
SIBN traded down $0.14 during trading hours on Wednesday, hitting $17.40. 389,536 shares of the stock were exchanged, compared to its average volume of 263,433. The stock has a 50-day simple moving average of $14.25 and a 200-day simple moving average of $17.34. SI-BONE, Inc. has a 12 month low of $11.89 and a 12 month high of $25.41. The stock has a market cap of $589.58 million, a price-to-earnings ratio of -8.83 and a beta of 1.35. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.90 and a quick ratio of 7.91.
SI-BONE (NASDAQ:SIBN – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.05). SI-BONE had a negative return on equity of 51.84% and a negative net margin of 69.36%. During the same period in the prior year, the firm earned ($0.42) EPS. Analysts anticipate that SI-BONE, Inc. will post -1.89 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Institutional Investors Weigh In On SI-BONE
A number of hedge funds have recently added to or reduced their stakes in SIBN. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in SI-BONE by 111.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,141 shares of the company’s stock valued at $94,000 after buying an additional 3,769 shares during the last quarter. Amalgamated Bank bought a new stake in SI-BONE in the first quarter valued at $120,000. AQR Capital Management LLC bought a new stake in SI-BONE in the second quarter valued at $157,000. BNP Paribas Arbitrage SA lifted its stake in SI-BONE by 19.2% in the fourth quarter. BNP Paribas Arbitrage SA now owns 7,139 shares of the company’s stock valued at $159,000 after buying an additional 1,148 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in SI-BONE by 15.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 12,949 shares of the company’s stock valued at $171,000 after buying an additional 1,712 shares during the last quarter. 99.36% of the stock is currently owned by institutional investors.
SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.
- Get a free copy of the StockNews.com research report on SI-BONE (SIBN)
- Lowe’s Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.